ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Xifaxan 550 mg Filmtabletten:Alfasigma Schweiz AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
A07AA11 - RifaximinATC-DDD Version 2016. Source: WHO
A - Alimentary Tract and Metabolism
 
A07 - Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents
 
A07A - Intestinal Antiinfectives

This group comprises locally acting antiinfectives. Antiinfectives for systemic use, see J - Antiinfectives for systemic use.
See also P - Antiparasitic products, insecticides and repellents.

A07AA - Antibiotics

Vancomycin and colistin for oral therapy are classified in this group as they are used in enterocolitis. Vancomycin injection/infusion is classified in J01XA - Glycopeptide antibacterials, and colistin injection/infusion in
J01XB - Polymyxins.
Most of the combined products containing more than one antibiotic, contain neomycin. Neomycin is given classification priority, thus all combined products containing neomycin and other antibiotics should be classified in A07AA51 - neomycin, combinations.
Paromomycin injection used in the treatment of leishmaniasis is classified here.

The DDDs are based on treatment of intestinal infections.

A07AA11 - Rifaximin
StärkeAdm.RouteNote
 O 
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home